ACSM
Rationale for New Drugs for Tuberculosis 500,000 cases annually of MDR TB – Second line treatment toxic and weak 15% of TB is HIV-related – Drug-drug interactions.
Johannesburg, 13 th August 2009 Outstanding Business Action to Stop TB: How Companies Contribute to the Global Fight 2009 TB Case Studies Shuma Panse Global.
World Bank, October 5, 2005 Tackling TB in the HIV era: implications for policy dialogue and operations Paul Nunn 5 October 2005.
